Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes? [PDF]
Vaccines, 2020 Whether the primary Hepatitis B vaccination confers lifelong protection is debated. The aim of the study was to assess the effectiveness of booster doses in mounting a protective HBV immune response in subjects vaccinated 18–20 years earlier.
Rosa Papadopoli +4 more
doaj +4 more sources
Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders [PDF]
Vaccines, 2023 Hepatitis B vaccine induces the production of antibodies against hepatitis B surface antigen (anti-HBs) and prevents hepatitis B virus (HBV) infection. However, 5–10% of individuals cannot develop anti-HBs even after multiple vaccinations (HB vaccine non-
Kana Shiraishi +14 more
doaj +2 more sources
Hepatitis B Surface Antibody (Anti-HBs) Kinetics during Rituximab Chemotherapy and Performance of Hepatitis B Vaccine before Immunosuppression: Two Prospective Studies [PDF]
Viruses, 2022 Rituximab promotes strong immunosuppression leading to a high risk of hepatitis B reactivation (HBV-R) and chronic infection. Current recommendations on HBV-R prevention are expensive and poorly individualized.
João Marcello de Araujo-Neto +3 more
doaj +2 more sources
Correlation between hepatitis B surface antibody (anti-HBs) in maternal blood and cord blood in newborn: a study on transplacental acquired maternal antibody [PDF]
BMC PediatricsBackground Hepatitis B Virus infection is a global health problem. Transplacental maternal antibodies can protect the infant early in life from infection. Objectives: This study investigates the correlation between maternal and infant Hepatitis B surface
Yudith Setiati Ermaya +7 more
doaj +2 more sources
Effect of Anti-HBs on Mortality Among Resolved HBV Infection: a Population-Based Prospective Cohort Study [PDF]
Infectious Diseases and Therapy, 2023 Introduction Surveillance programs after hepatitis B surface antigen (HBsAg) loss are not yet well established, and the role of hepatitis B surface antibodies (anti-HBs) remains controversial. We aimed to evaluate the risk factors for increased mortality
Shuai-Wen Huang +4 more
doaj +2 more sources
The Investigation of HBV Pre-S/S Gene Mutations in Occult HBV Infected Blood Donors with anti-HBs Positive [PDF]
Canadian Journal of Infectious Diseases and Medical Microbiology, 2022 Introduction. The coexistence of hepatitis B virus (HBV) and hepatitis B surface antibodies (anti-HBs) in occult hepatitis B virus infection (OBI) is a contradictory phenomenon, and the underlying mechanism is not fully understood. The characteristics of
Yan Guo +6 more
doaj +2 more sources
Factors influencing the utilisation of anti-HBs titre testing services among nursing students in Northwest Ghana: A cross-sectional study. [PDF]
PLOS Global Public HealthUnderstanding the impact of hepatitis B testing, vaccination, the number of vaccine doses, and socio-demographics on post-vaccination anti-HBs titre testing, is essential for hepatitis B prevention. The aim of the study was to determine the prevalence of
Augustine Ngmenemandel Balegha
doaj +2 more sources
Transplacentally acquired maternal antibody against hepatitis B surface antigen in infants and its influence on the response to hepatitis B vaccine. [PDF]
PLoS ONE, 2011 BACKGROUND: Passively acquired maternal antibodies in infants may inhibit active immune responses to vaccines. Whether maternal antibody against hepatitis B surface antigen (anti-HBs) in infants may influence the long-term immunogenicity of hepatitis B ...
Zhiqun Wang +6 more
doaj +1 more source
Advances in Rheumatology, 2021 Background Hepatitis B virus (HBV) reactivation consequent to immunosuppressive therapy is an increasingly prevalent problem with serious clinical implications.
Ming-Hui Hung +2 more
doaj +1 more source
In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee [PDF]
, 1999 A 35-year-old female hepatitis B virus carrier chimpanzee was infused with one dose of a mixture of human monoclonal antibodies 9H9 and 4-7B (antibodies against hepatitis B virus surface antigen; HBsAg).
Bergen, P.A.C. (Patrick) van +8 more
core +12 more sources